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Objective: To determine whether plasma homocysteine
(Hcy) concentration is associated withmild parkinsonian
signs (MPS) in community-dwelling elderly individuals.
Design: Cross-sectional analyses of a population-
based cohort study.
Setting: Washington Heights–Inwood, New York.
Patients: Persons without dementia 65 years and older.
Main Outcome Measure: Participants underwent an
abbreviatedmotor portion of theUnified Parkinson’s Dis-
ease Rating Scale. Each participant was assigned anMPS
score (range, 0-40). The Hcy concentration was mea-
sured from plasma. All analyses were cross-sectional.
Results: There were 369 participants (mean±SD age,
77.8±6.0years;mean±SDMPSscore,1.51±2.55;mean±SD
plasma Hcy concentration, 17.3±6.5 µmol/L). Mean±SD
MPS scores in plasma Hcy concentration quintiles were
as follows: lowest quintile, 1.15±1.77; second quintile,
1.18±1.88; third quintile, 1.64±2.93; fourth quintile,
1.45±2.17; andhighest quintile, 2.12±3.49 (84.3%higher
than 1.15) (P=.02). In an unadjusted linear regression
model, plasmaHcy concentrationwas associatedwith log
MPS score (dependent variable) (P=.008). In a linear re-
gression model that adjusted for confounding variables,
plasma Hcy concentration was associated with log MPS
score (P=.04).
Conclusions: These data indicate that MPS are associ-
ated with higher plasma Hcy concentrations. Prospective
neuroimaging aswell as clinical-pathological studieswould
furtherourunderstandingof severalmechanisms that could
underlie the observed association.
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M ILD PARKINSONIANsigns (MPS),which in-clude impaired gaitand balance, rigidity,bradykinesia, and rest
tremor, are commonly found during the
clinical examination of older people who
do not have any diagnosed neurological
disease.1-7 These signs, which are highly
prevalent, are associated with functional
disability8,9 and increased risks for demen-
tia5,7 and mortality.2,10 The processes that
underlie MPS are not clear but could in-
clude an age-associated decline in nigro-
striatal dopaminergic activity, the devel-
opment of degenerative (eg, Lewy body or
Alzheimer type) pathological changes, or
the accumulation of vascular pathologi-
cal changes in the cerebral subcortical
white matter or other brain regions. El-
evated homocysteine (Hcy) concentra-
tion is a cerebrovascular risk factor but it
has also been associated with treated and
untreatedParkinsondisease (PD).11,12With
one possible exception,12 to our knowl-
edge plasma Hcy concentrations have not
been assessed in elderly individuals with
MPS nor have we previously assessed the
association between these concentra-
tions andMPS in our cohorts in northern
Manhattan, New York. A recent cross-
sectional study in 3 French cities demon-
strated an association between elevated
plasma Hcy concentration and slower
walking speed in elderly individuals.12 In
that study,12 however, investigators fo-
cused on gait speed rather than MPS. We
studied a sample of elderly persons with-
out dementia living in Washington
Heights–Inwood, New York, to deter-
mine specificallywhetherplasmaHcy con-
centration is associated with MPS.
METHODS
STUDY SAMPLE
Participants in the Washington Heights–
Inwood Columbia Aging Project cohort were
drawn by random stratified sampling of healthy
Medicare beneficiaries 65 years or older resid-
ingwithin ageographicallydefinedareaofnorth-
ern Manhattan. The sampling procedures have
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been described elsewhere.1,13 The participantswere recruited be-
tween 1992 and 1994, and 2126 were enrolled. Their mean±SD
agewas 77.2±7.2 years,mean±SD educationwas 8.2±4.9 years,
69.4% were women, and 20.7% were non-Hispanic white. Each
participant underwent a structured interview of health and func-
tion at the time of study entry and, over the ensuing year, was
referred for thesamestandardizedneurological examination,which
included an abbreviated, 10-item version of the motor portion
of the Unified Parkinson’s Disease Rating Scale (UPDRS).14
We excluded data on 1104 participants. First, we excluded
data from 676 individuals who screened negative for dementia,
PD, or stroke orwhohaddied orwere lost to follow-up and there-
fore did not receive the standardized neurological examination.
Second, data on an additional 44 participants were excluded be-
cause of incomplete neurological examinations. Third, we ex-
cluded data from 53 participants who were taking a neuroleptic
medication because parkinsonian signs can result from the use
of these medications. Fourth, we assigned a diagnosis of PD or
Parkinson plus syndrome based on research criteria15 and par-
ticipants were considered to have PD or Parkinson plus syn-
drome if (1) they had previously received a diagnosis of PD or
Parkinsonplus syndromeor (2) theyhadon the standardizedneu-
rological examination 2 ormore cardinal signs of parkinsonism.
Cardinal signswere bradykinesia, rigidity, postural changes, and
rest tremor. A cardinal signwas considered to be present when 1
UPDRS rating was 2, 3, or 4. Fourteen (1.0%) of the remaining
1353 participants had a diagnosis of PD or a Parkinson plus syn-
drome, which is consistent with a prevalence of 0.7% to 1.2% for
PD, which has been reported for persons 65 years and older in
northern Manhattan.16 These 14 participants were excluded be-
cause our intentionwas to study a community populationof older
people without these diseases. Fifth, all participants also under-
went a standardizedneuropsychological battery.17Using these test
results as well as clinical information, a consensus diagnosis of
dementia was assigned if participants met established criteria18
and if functional difficulties could be attributed to cognitive rather
thanphysical disability.19 AClinicalDementiaRating (CDR) score
was assigned aswell.We excluded 227 participantswith demen-
tia. After the exclusionof 1014participants, the remaining sample
comprised 1112 potential participants.
A sample of 909 participants from the original cohort of 2126
had been selected randomly at the time of their baseline as-
sessment to conduct a study of Hcy concentration in elderly
individuals.20 Of the 1112 remaining potential participants, 369
(33.2%) had been selected for the plasma Hcy concentration
study. Therefore, our final sample comprised these 369 par-
ticipants. The study was approved by our institution’s internal
review board and written consent was obtained from all
participants.
EVALUATION
As noted earlier, a standardized neurological examination was
conducted by 1 of 3 neurologists, including an abbreviated, 10-
item version of themotor portion of the UPDRS.14 The 10 items
included speech, facial expression, tremor at rest (1 item), ri-
gidity (rated separately in the neck, right arm, left arm, right
leg, and left leg), posture, and body (axial) bradykinesia.1 Each
of the 10 items was rated from 0 to 4. A rating of 1 indicated a
mild abnormality and a rating of 2 or more indicated an ab-
normality of moderate or greater severity. Reliability of assess-
ment of parkinsonian signs by 3 neurologists has been re-
ported andwas acceptable (intraclass correlation coefficient for
total motor score=0.82).21 AnMPS score (range, 0-40) was cal-
culated for each participant.
Demographic data were collected, including age and sex.
Ethnic group was based on self-report using the format of the
1990 US census.22 Individuals were asked whether they were
of Hispanic origin. Participants were then assigned to 1 of the
following ethnic groups: non-Hispanic black, Hispanic, non-
Hispanic white, and other. Number of years of education was
obtained by self-report. Presence of a history of diabetes melli-
tus, hypertension, stroke, heart disease (myocardial infarction
or congestive heart failure), or arthritis was assessed by self-
report, as was use of nonsteroidal anti-inflammatory drugs (ever
vs never). Participants were asked whether they smoked ciga-
rettes (coded as ever [including current or past smokers] vs
never) or regularly used ethanol (ever vs never).
PLASMA Hcy AND OTHER PLASMA AND
SERUM CONCENTRATIONS
Fasting blood was drawn at baseline in EDTA tubes. Within 2
hours of collection, it was centrifuged, separated into plasma
aliquots, and stored at −70°C. The Hcy concentration wasmea-
sured from stored plasma using high-performance liquid chro-
matography with fluorescence detection.23 Plasma concentra-
tions of folate and vitamin B12 were determined by radioassay
(Simultrac; ICN Pharmaceuticals, Costa Mesa, California). Se-
rum creatinine concentration was measured by spectrophoto-
metric assay (Sigma, St Louis, Missouri).
STATISTICAL ANALYSES
These cross-sectional statistical analyseswere performed in SPSS
(version 13.0; SPSS Inc, Chicago, Illinois). The MPS score had
a value of 0 in 204 of 369 participants, which could violate one
of the assumptions that justify the use of linear regressionmod-
eling. Therefore, for our linear regression models, we added
the value 1.0 to the value in all 369 participants and then log
transformed (log10) this modified MPS score.
In a linear regression model, we examined the association
between MPS score categories (0, 1, 2, 3, 4, !5) and plasma
Hcy concentration. In an additional analysis, plasma Hcy con-
centrationwasdivided into quintiles ("12.115µmol/L,#12.115
to "14.080 µmol/L, #14.080 to "16.555 µmol/L, #16.555
to$20.111 µmol/L, and#20.111 µmol/L [to convert to mil-
ligrams per liter, divide by 7.397]), and in a linear regression
model, we examined the association between plasma Hcy con-
centration quintile and log MPS score (dependent variable).
An unadjusted linear regression analysis was performedwith
log MPS score as the dependent variable and plasma Hcy con-
centration as the independent variable.We then considered pos-
sible covariates that were confounders or mediators; in these
analyses, becauseMPS scorewas not normally distributed, Spear-
man correlation coefficients (r) were used to assess associa-
tions between the MPS score and continuous covariates (eg,
age) and Mann-Whitney U tests or Kruskal-Wallis tests were
used to assess associations between the MPS score and cat-
egorical covariates (eg, sex). Covariates that we consideredwere
age in years; sex; ethnic group (non-Hispanic black, Hispanic,
non-Hispanicwhite, and other); years of education; regular etha-
nol use (ever vs never); cigarette use (ever vs never); history
of stroke, arthritis, diabetes, hypertension, or heart disease; non-
steroidal anti-inflammatory drug use (ever vs never); CDR score
(0 or 0.5); plasma folate and vitamin B12 concentrations; and
serumcreatinine concentration. These analyses identified 4 vari-
ables that were associated with MPS score: age, diabetes melli-
tus, heart disease, and CDR score (Table). Each of these 4 vari-
ables was then placed in a linear regression model along with
plasma Hcy concentration (log MPS score=dependent vari-
able), and in these 4 models (each with 2 independent vari-
ables: plasma Hcy concentration and 1 of the 4 confounding
variables), the association between plasma Hcy concentration
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and log MPS score remained robust, indicating that these con-
founding variables were not likely to be mediators. We then
performed linear regression analyses (logMPS score=dependent
variable) that adjusted simultaneously for age, diabetes melli-
tus, heart disease, and CDR score. To further test whether vas-
cular disorders (diabetes mellitus, heart disease, hyperten-
sion, and stroke)weremediators, in 4 linear regression analyses,
we excluded participants with these vascular disorders and ex-
amined the association between plasmaHcy concentration and
log MPS score. In some analyses, we also stratified by age into
4 strata.
RESULTS
There were 369 participants. Their mean±SD age was
77.8±6.0 years, mean±SD education was 7.9±4.7 years,
and 68 (18.4%)were non-Hispanicwhite,whichwas simi-
lar to the original cohort of 2126 from which they were
derived. Two-hundred seventy-five (74.5%)werewomen,
which is 5.1% higher than the original cohort (69.2%);
because of the large size of the comparison groups, this
modest difference reachedmarginal significance (P=.046).
None had PD or dementia and none was receiving le-
vodopa therapy. Themean±SDMPS scorewas 1.51±2.55
(range, 0-18). The MPS score was 0 in 204 participants
(55.3%), 1 in 39 (10.6%), 2 in 45 (12.2%), 3 in 27 (7.3%),
4 in 18 (4.9%), and 5 or higher in the remaining 36 par-
ticipants (9.8%). The mean±SD plasma Hcy concentra-
tion was 17.3±6.5 µmol/L (range, 8.3-54.1 µmol/L). The
median latency between the 10-item version of the mo-
tor portion of the UPDRS and phlebotomy was 41 days
(interquartile range, 18-71 days), indicating that the 2
events were separated by only a modest interval.
LogMPS score was associatedwith age andwas higher
in participants with diabetes mellitus, heart disease, or a
CDR score of 0.5 (Table). PlasmaHcy concentration was
higher in men and ethanol users; it was also associated
with plasma concentrations of folate and vitamin B12 and
serum creatinine concentration (Table).
Higher MPS score was associated with higher plasma
Hcy concentration (Figure 1). For example, for anMPS
score of 0, the mean±SD plasma Hcy concentration was
16.2±6.7 µmol/L;MPS score of 1, 17.3±7.7 µmol/L;MPS
score of 2, 18.5±8.4 µmol/L; MPS score of 3, 17.0±8.3
µmol/L;MPS score of 4, 15.1±3.3 µmol/L; andMPS score
of 5 or higher, 20.2±11.0 µmol/L (linear regression analy-
sis,%=0.56;P=.02). PlasmaHcy concentrationwas strati-
fied into quintiles (Figure 2); the mean±SDMPS score
in each quintile was as follows: lowest plasma Hcy con-
centration quintile, 1.15 ± 1.77; second quintile,










Age 369 r=0.26a r=.08
Sex
M 94 0.23±0.34 18.5±7.8b
F 275 0.27±0.32 16.5±7.6
Race
Non-Hispanic white 68 0.25±0.34 16.7±7.2
Non-Hispanic black 110 0.27±0.34 18.1±9.4
Hispanic 189 0.26±0.31 16.4±6.6
Other 2 0.00±0.00 16.3±4.9
Years of education 369 r=−0.07 r=−0.01
Arthritis
No 117 0.23±0.33 17.1±6.7
Yes 252 0.27±0.32 16.9±8.1
Diabetes mellitus
No 300 0.23±0.31c 16.8±7.4
Yes 69 0.37±0.37 17.5±8.9
Hypertension
No 150 0.25±0.32 16.6±7.5
Yes 219 0.27±0.33 17.3±7.8
Heart disease
No 286 0.23±0.31c 16.9±7.2
Yes 40 0.37±0.33 16.9±6.7
Stroke
No 325 0.25±0.32 16.8±7.2
Yes 44 0.29±0.34 18.3±10.7
Regular ethanol use
No 318 0.25±0.32 16.4±6.4c
Yes 51 0.29±0.34 20.4±12.8
Smoked cigarettes
No 251 0.26±0.32 16.6±7.8
Yes 118 0.25±0.33 17.7±7.4
NSAID use
No 327 0.25±0.33 17.1±7.9
Yes 42 0.30±0.30 15.8±5.5
CDR score
0 292 0.21±0.30a 16.8±7.2










Abbreviations: CDR, Clinical Dementia Rating; MPS, mild parkinsonian


















Figure 1. Scatter plot of mild parkinsonian signs (MPS) score by plasma
homocysteine concentration in men and women. Fit line for men is depicted
by a broken line; fit line for women is depicted by a solid line.
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1.18±1.88; third quintile, 1.64±2.93; fourth quintile,
1.45±2.17; andhighest quintile, 2.12±3.49 (84.3%higher
than 1.15) (linear regression analysis for MPS score,
%=0.022;P=.02 and linear regression analysis for logMPS
score,%=0.025; P=.03). Themean±SDMPS scores in the
highest vs lowest plasmaHcy concentration quintile were
2.12±3.49 vs 1.15±1.77 (84.3% difference).Within each
of the 4 age strata ($74, 74-77, 78-82, and#82 years),
MPS scores in the lowest vs highest plasma Hcy concen-
tration quintile were 1.25±1.80 vs 1.47±2.70 (17.3% dif-
ference) ($74 years); 0.59±1.73 vs 1.69±3.35 (175.3%
difference) (age 74-77 years); 0.80±1.24 vs 2.28±3.68
(184.7% difference) (age 78-82 years); and 2.33±2.10 vs
3.00±4.00 (28.6% difference) (#82 years) (Figure 3).
In an unadjusted linear regressionmodel, plasmaHcy
concentration was associated with log MPS score (de-
pendent variable) (%=0.006; P=.008). In a linear regres-
sion model that adjusted for covariates that were asso-
ciatedwith logMPS score at theP$ .10 level (age, diabetes
mellitus, heart disease, and CDR score [Table]), plasma
Hcy concentration was associated with log MPS score
(%=0.004; P=.04). In the adjusted model, 3 of the 4 co-
variates were also associated with log MPS score: age
(%=0.011;P$.001), diabetesmellitus (%=0.135;P=.001),
heart disease (%=0.006;P=.30), andCDRscore (%=0.036;
P$ .001). In a model that adjusted simultaneously for
age and CDR score as well as multiple vascular disor-
ders (diabetes mellitus, heart disease, hypertension, and
stroke), plasma Hcy concentration was associated with
log MPS score (%=0.004; P=.04). Finally, in 4 linear re-
gression analyses that excluded participants with each
of the 4 vascular disorders (eg, analysis 1 excluded par-
ticipants with diabetes mellitus and analysis 2 excluded
participants with heart disease), the association be-
tween plasma Hcy concentration and logMPS score per-
sisted (data not shown).
Besides adjusting for age in our linear regressionmod-
els, we also stratified the sample based on age ($74, 74-
77, 78-82, and #82 years). Within each of these 4 age
strata, the % values for the association between plasma
Hcy concentration and log MPS score remained un-
changed, further indicating that the association was not
due to the confounding effects of age.
COMMENT
We studied a group of community-dwelling elderly per-
sonswithout dementia in northernManhattan. None had
PD or a Parkinson plus syndrome and none were using
levodopa. Our data show that elevated plasma Hcy con-
centration was associated with MPS.
The mean difference in MPS score between the high-
est vs lowest plasmaHcy concentration quintile was 0.97
points (2.12 vs 1.15), which was an 84.3% increase. This
difference is greater than the difference we have re-
ported in the MPS scores of smokers vs nonsmokers (a
77.8% difference).1 We have previously shown that an
increase in MPS score from 1 to 2 is associated with a
reduction in several functional measures (15% reduc-
tion in Active Life Expectancy Score and 10% increase
in the timed chair stand test score), indicating that this
small absolute difference in MPS score can have func-
tional consequences.8
The mechanism that underlies the observed associa-
tion is not clear but there are several possibilities. First,
elevated plasma Hcy concentration could result in MPS.
This could either be a direct cause or through an inter-
mediate step (eg, vascular disease [strokes] or some other
unknown factor). Arguing against strokes are our data,
which suggest that vascular factors are notmediating this
association. Second,MPS could result in elevated plasma
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Figure 2. Mild parkinsonian signs (MPS) score by plasma homocysteine
concentration quintile in men and women. Each bar represents 2 SEs and
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Figure 3. Within each of the 4 age strata ($74, 74-77, 78-82, and #82
years), mean±SD mild parkinsonian signs (MPS) scores in the lowest vs
highest plasma homocysteine concentration quintile were: 1.25±1.80 vs
1.47±2.70 (17.3% difference) ($74 years), 0.59±1.73 vs 1.69±3.35
(175.3% difference) (age 74-77 years), 0.80±1.24 vs 2.28±3.68 (184.7%
difference) (age 78-82 years), and 2.33±2.10 vs 3.00±4.00 (28.6%
difference) (#82 years). Lowest quintiles are depicted by dashed bars and
highest quintiles, by solid bars.
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biologically plausible. Third, elevated plasma Hcy con-
centration andMPS may be associated with one another
yet one may not cause the other. For example, elevated
plasma Hcy concentration and MPS could both be due
to underlying vascular disease, Lewybodies, or someother
unknown factor. Possibilities 1 and 2 imply a causal con-
nection between plasma Hcy concentrations and MPS,
whereas possibility 3 suggests an associationwithout cau-
sation (ie, elevated plasma Hcy concentrations andMPS
may each be markers of a common underlying process).
Elevated plasma Hcy concentration is often viewed as
a marker of cerebrovascular risk.12 There are a variety of
types of evidence for a vascular etiology for MPS. It is
well known thatmore severe forms of parkinsonism, such
as vascular parkinsonism, can occur in the setting of basal
ganglia infarcts or deep white matter ischemic le-
sions.24-28 With regard to normal elderly persons, there
have been several epidemiological studies examining the
associations between vascular risk factors or vascular dis-
ease and milder parkinsonian signs. In one study,29 el-
derly individuals with rigidity and gait disturbance were
compared with their counterparts without these signs,
and they were more likely to have hypertension and re-
duced high-density lipoprotein levels. In a second study,30
the relation between diabetes mellitus and MPS was as-
sessed prospectively in older Catholic clergy without PD
or dementia; the investigators found that diabetes was
associated with progression of rigidity and gait distur-
bance. Finally, in a study of 2776 elderly residents of
northernManhattan enrolled between 1999 and 2001,31
diabetes, heart disease, peripheral vascular disease, and
strokeweremore prevalent in participants withMPS than
in thosewithoutMPS, whereas nonvascular diseaseswere
no more prevalent; furthermore, the number of vascu-
lar diseases was associated with MPS (odds ratio, 1.31;
95% confidence interval, 1.18-1.46;P$ .001). The com-
bination of diabetes mellitus and heart diseases in-
creased the odds of MPS by 70% and the combination of
these with stroke increased the odds by 3-fold.31
Elevated plasma Hcy concentration has also been re-
ported to occur in treated and untreated PD.11 Hence, el-
evated plasma Hcy concentrationmay be a feature of pa-
tientswith Lewy bodies. It is not known, however, towhat
extent MPS occur as a marker of underlying emerging
Lewy bodies.
Our findings extend those of the recent French study
that found that higher plasma Hcy concentrations were
associatedwith slowerwalking speed.12While slowwalk-
ing speed should not necessarily be equated with par-
kinsonism, patients with parkinsonism often manifest
slow walking speed. In another study,32 Hcy concentra-
tionwas associatedwith a globalmeasure of physical per-
formance. Thatmeasure included a variety of tests of bal-
ance, gait, lower body strength and coordination, and
manual dexterity, although not MPS per se.
Our findings raise the question as towhetherMPSmay
be prevented by lowering plasma Hcy concentrations.
Plasma Hcy concentration can be lowered with vitamin
B6, vitamin B12, and folate supplementation, but results
of a trial of these vitamin supplements to lower Hcy con-
centrations in the secondary prevention of stroke were
negative.33
As discussed earlier, one of the potential mecha-
nisms linking plasma Hcy concentration to MPS is cere-
brovascular disease.Mean plasmaHcy concentrationwas
1.5 µmol/L higher in participants with a history of stroke
vs those without such a history, but the difference was
not significant (P=.20). We believe that the lack of sta-
tistical significancewas due to the relatively small sample
size and the use of clinical history rather than brain
imaging data to ascertain cerebrovascular disease. This
likely resulted in an underestimation of the true preva-
lence of cerebrovascular disease, thereby biasing our re-
sults toward the finding of a nonsignificant difference in
plasma Hcy concentration between participants with vs
without stroke. Ideally, our study should be replicated
in a sample with brain imaging data to assess subclinical
cerebrovascular disease.
This studyhad anumber of limitations. First, our analy-
ses were cross-sectional. This does not lessen the valid-
ity of the association we observed but places limitations
on our ability to study its underlyingmechanisms. More
specifically, longitudinal analyses would have allowed us
to assess whether higher plasma Hcy concentration is a
risk factor for subsequent development of MPS, or con-
versely, whetherMPS are a risk factor for subsequent de-
velopment of elevated plasma Hcy concentration. Bio-
logically, the former rather than latter explanation ismore
plausible but this cannot be directly addressed by the cur-
rent analyses. Brain imaging studies (eg, magnetic reso-
nance imaging) or postmortem studies would also al-
low one to further examine the possible biological bases
(vascular vs Lewy body) for the association we ob-
served. However, we do not have these types of data. Sec-
ond, only about one-third of our sample of 1112 poten-
tial participants had had plasma Hcy concentration
measurements, raising the issue of selection bias. Argu-
ingmost strongly against this is that the participants who
underwent phlebotomy for Hcy concentration had been
selected randomly. Furthermore, the age and educa-
tional characteristics of our final sample of 369 partici-
pants were similar to those of the initial sample of 2126.
A small percentage difference in the proportion ofwomen
reached statistical significance in these large sample size
comparisons. Sex, however, was not associated with our
outcome variable, MPS. Women did have lower plasma
Hcy concentrations (and less variance in these concen-
trations) than men. Hence, in a sample that was slightly
enriched in women, as ours was, this lower variance in
one of the primary variables (plasma Hcy concentra-
tion) may havemade it more difficult for us to detect the
association betweenHcy concentrations andMPS. Third,
our blood samples were centrifuged, aliquoted, and fro-
zen within 2 hours rather than 30 minutes of collection.
This 2-hour processing time could have resulted in el-
evated Hcy concentrations. However, we have no rea-
son to suspect that processing timewas differential across
MPS strata. Finally, prior work has indicated that MPS
comprise several discrete factors (eg, tremor, rigidity, bra-
dykinesia).6While it would have been interesting to have
examined the association betweenMPS and each of these
factors, our study was not sufficiently powered for these
analyses. Despite these limitations, this study is one of
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few that have examined the associations between plasma
Hcy concentrations andmotor signs in elderly individu-
als. Its strengths include the population-based design, the
careful assessment ofMPS in several hundred elderly per-
sons, the exclusion of participantswith dementia and par-
kinsonism, and the adjustment for a variety of potential
confounding variables.
In summary, we provide evidence of an association be-
tweenMPS and elevated plasmaHcy concentrations. Pro-
spective neuroimaging aswell as clinical-pathological stud-
ies are now needed to further our understanding of
mechanisms that may underlie this association.
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